Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synergy: ALPN-101 in Systemic Lupus Erythematosus
NCT04835441Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 7
01
Overview
A Phase 2 trial of acazicolcept in systemic lupus erythematosus (SLE), sponsored by Vertex Pharmaceuticals. Started Jun 2021; status: completed.
02
Drugs
acazicolcept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04835441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835441.